NLRP3 inflammasome activation in macrophage cell lines by prion protein fibrils as the source of IL-1β and neuronal toxicity

I Hafner-Bratkovič, M Benčina, KA Fitzgerald… - Cellular and molecular …, 2012 - Springer
I Hafner-Bratkovič, M Benčina, KA Fitzgerald, D Golenbock, R Jerala
Cellular and molecular life sciences, 2012Springer
Prion diseases are fatal transmissible neurodegenerative diseases, characterized by
aggregation of the pathological form of prion protein, spongiform degeneration, and
neuronal loss, and activation of astrocytes and microglia. Microglia can clear prion plaques,
but on the other hand cause neuronal death via release of neurotoxic species. Elevated
expression of the proinflammatory cytokine IL-1β has been observed in brains affected by
several prion diseases, and IL-1R-deficiency significantly prolonged the onset of the …
Abstract
Prion diseases are fatal transmissible neurodegenerative diseases, characterized by aggregation of the pathological form of prion protein, spongiform degeneration, and neuronal loss, and activation of astrocytes and microglia. Microglia can clear prion plaques, but on the other hand cause neuronal death via release of neurotoxic species. Elevated expression of the proinflammatory cytokine IL-1β has been observed in brains affected by several prion diseases, and IL-1R-deficiency significantly prolonged the onset of the neurodegeneration in mice. We show that microglial cells stimulated by prion protein (PrP) fibrils induced neuronal toxicity. Microglia and macrophages release IL-1β upon stimulation by PrP fibrils, which depends on the NLRP3 inflammasome. Activation of NLRP3 inflammasome by PrP fibrils requires depletion of intracellular K+, and requires phagocytosis of PrP fibrils and consecutive lysosome destabilization. Among the well-defined molecular forms of PrP, the strongest NLRP3 activation was observed by fibrils, followed by aggregates, while neither native monomeric nor oligomeric PrP were able to activate the NLRP3 inflammasome. Our results together with previous studies on IL-1R-deficient mice suggest the IL-1 signaling pathway as the perspective target for the therapy of prion disease.
Springer